Last reviewed · How we verify

NCT06372509: PMCD

A Proteomic Analysis for Understanding the Link Between Migraine and Cardiovascular Disease

Recruiting now Last updated 1 May 2024
What this trial tests

trial in Coronary Artery Disease in 90 participants. Currently enrolling.

Timeline
3 April 2024
Primary endpoint
30 October 2025
30 October 2025

Quick facts

Lead sponsorCentro Cardiologico Monzino
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment90
Start date3 April 2024
Primary completion30 October 2025
Estimated completion30 October 2025
Sites1 location across Italy

Conditions studied

Sponsor

Centro Cardiologico Monzino — full company profile →

Who can join

Adults 25 to 60, any sex, with Coronary Artery Disease or Migraine. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicenter, prospective observational study. Will be collecting data from 90 consecutive patients (aged 25- 60 years ) with and without migraine admitted at our Hospital. Primary aim of the study will be to assess the correlation between migraine and proteomic profiling of plasma and their possible correlation with known cardio and cerebrovascular disease and Cardiovascular (CV) risk factors.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

Other Centro Cardiologico Monzino trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06372509.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing